IUPAC Traditional

N-(4,5-dihydro-1,3-thiazol-2-yl)cyclohexanecarboxamide

Compound number MolPort-001-540-541
Molecular weight 212.31
InChI key CPGJCOKLIMIVBU-UHFFFAOYSA-N
Molecular formula C10H16N2OS
DMSO Solubility Unknown
SMILES O=C(NC1=NCCS1)C1CCCCC1 |t:3|
Best offer
$253.00
Including direct shipping

Pack size:
1 micromol
Shipping to:
United States
Lead time:
16 business days
Adjust Requirements

Vitas M Chemical Limited

Direct S&H to USA
220.00 USD
Catalog
Screening compound
Ships out
16 business days
Purity
>90%
Last updated
today
In warehouse
32.00 mg

Supplier Catalogue Data

Pack size
Ships out
Price
Quantity
1 micromol
March 3, 2023
33.00 USD
2 micromol
March 3, 2023
33.00 USD
3 micromol
March 3, 2023
33.00 USD
Simpler, smarter compound sourcing with Molport
  • Extensive vetted supplier network
  • Smart standardised systems and intelligent fulfilment
  • Experienced support and expert lab services
We supply companies including
Fraunhofer logo Domainex logo Reverie labs logo
Search and order chemical compounds instantly
View search options
Access and search our databases offline
Access databases

More Information

Compound identifiers

Compound number
MolPort-001-540-541

Names, Synonyms and 3rd Party Identifiers

Name
Cyclohexanecarboxylic acid (4,5-dihydro-thiazol-2-yl)-amide
N-(4,5-dihydro-1,3-thiazol-2-yl)cyclohexanecarboxamide
cyclohexyl-N-(1,3-thiazolin-2-yl)carboxamide
MFCD01734650

InChI

InChI
1/C10H16N2OS/c13-9(8-4-2-1-3-5-8)12-10-11-6-7-14-10/h8H,1-7H2,(H,11,12,13)
InChI key
CPGJCOKLIMIVBU-UHFFFAOYSA-N

Formula

Molecular formula
C10H16N2OS
Molecular weight
212.31

Molport Guarantee

When you purchase products through the Molport website from any seller other than Molport itself, you will be protected by the Molport Guarantee. If you purchase products from Molport itself, this Molport Guarantee will not apply, and your remedies will be governed by the Molport Terms of Sale and Supply.

We use cookies to improve your experience on our websites and for advertising. By clicking "Accept All", you consent to our use of cookies. Learn more.

Feedback